Changes in the morphological structure of giant prolactinoma during treatment with cabergoline

Currently, cabergoline therapy is the main method of treatment with prolactin. The use of the drug in most cases leads to tumor regression, normalization of prolactin levels and restoration of gonadotropic function. The mechanism of its impact on tumor cells in vivo, which is dynamically traced in the same human tumor, is the case of considerable interest. We observed a 30-year-old patient who was operated on twice for a giant prolactinoma before and on treatment by cabergoline. The morphological study after the first surgery (before introducing of cabergoline therapy) revealed a prolactin-positive pituitary tumor with a Ki-67 labeling index of 8% and with strong expression of dopamine type 2 receptors (D2R), CD31 and CD34. After 4 months, during which the patient received cabergoline at a dose starting from 0.5 mg to 1.5 mg per week, a second transsphenoidal surgery was performed with subtotal removal of residual tumor tissue. During the morphological study of the second biopsy sample, the tumor retained a pronounced immunopositivity to prolactin and D2R, with a decrease in the labeling index Ki-67 to 2%, as well as a decrease in the expression of CD31 and CD34. Subsequent cabergoline therapyresulted in persistent normoprolactinemia, restoration of androgen (and reproductive) status, and no tumor recurrence over a 10-year period on cabergoline treatment. Thus, one of the mechanisms of effect of cabergoline that leads to tumor regression is a decrease in the proliferative index and angiogenesis of the tumor.

1. Corsello SM, Ubertini G, Altomare M, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf). 2003;58(5):662−670. doi: 10.1046/j.1365-2265.2003.01770.x.

2. Shrivastava RK, Arginteanu MS, King WA, et al. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97(2):299–306. doi: 10.3171/jns.2002.97.2.0299.

3. Ines M, Millán P, Cristina C, et al. Role of VEGF, FGF-2 and CD31(2014). In: Hayat M.A., ed. Tumors of the central nervous system. Vol. 12. Molecular mechanisms, children’s cancer, treatments, and radiosurgery. Springer, Dordrecht; 2014. Р. 33−41. doi: 10.1007/978-94-007-7217-5_3.

4. Shimon I. Giant prolactinomas: Multi-modal approach to achieve tumor control. Endocrine. 2017;56(2):227−228. doi: 10.1007/s12020-016-1225-x.

5. Астафьева Л.И., Кадашев Б.А., Калинин П.Л., и др. Выбор тактики лечения гигантских пролактинсекретирующих аденом гипофиза // Вопросы нейрохирургии им. Н.Н. Бурденко. — 2009. — №2. — С. 23−28. [Astafieva LI, Kadashev BA, Kalinin PL, et al. Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas. Burdenko’s journal of neurosurgery. 2009;(2):23−28. (In Russ).]

6. Quadri SK, Meites J. Regression of spontaneous mammary tumors in rats by ergot drugs. Proc Soc Exp Biol Med. 1971;138(3):999−1001. doi: 10.3181/00379727-138-36036.

7. Barrow DL, Tindall GT, Kovacs K, et al. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors. J Neurosurg. 1984;60(1):1−7. doi: 10.3171/jns.1984.60.1.0001

8. Rengachary SS, Tomita T, Jefferies B, et al. Structural changes in human pituitary tumor after bromocriptine therapy. Neurosurgery. 1982;10(2):242–251.

9. Tindall GT, Kovacs K, Horvath E, et al. Human prolactin-producing adenomas and bromocriptine: a histological, immuno-cytochemical, ultrastructural and morphometric study. J Clin Endocrinol Metab. 1982;55(6):1178–1183. doi: 10.1210/jcem-55-6-1178.

10. Kontogeorgos G, Sambaziotis D, Piaditis G, et al. Apoptosis in human pituitary adenomas: a morphological and in-situ end-labeling study. Mod Pathol. 1997;10(9):921–926.

11. Gen M, Uozumi T, Ohta M, et al. Necrotic changes in prolactinomas after long term administration of bromocriptine. J Clin Endocrinol Metab. 1983;59(3):463–479. doi: 10.1210/jcem-59-3-463.

12. Losa M, Franzin A, Mortini P, et al. Usefulness of markers of cell proliferation in the management of pituitary adenomas. Clin Sci (Lond). 1998;95(2):129–135.

13. Burian K, Pendl G, Salah S. The recurrence of pituitary adenoma after transfrontal, transphenoidal or 2-stage combined operation. Wien Med Wochenschr. 1970;120(47):833−836.

14. Кадашев Б.А., Трунин Ю.К., Корниенко В.И., и др. Поэтапное применение транскраниального и транссфеноидального хирургических доступов в лечении аденом гипофиза // Вопросы нейрохирургии им. Н.Н. Бурденко. — 1996. — №4. — С. 6−10. [Kadashev BA, Trunin YuK, Kornienko VI, et al. Poetapnoye primeneniye transkranial’nogo i transsfenoidal’nogo khirurgicheskikh dostupov v lechenii adenom gipofiza. Burdenko’s journal of neurosurgery. 1996;(4):6−10. (In Russ).]

15. Eguchi K, Kawamoto K, Uozumi T, et al. Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. Endocr J. 1995;42(3):413−420. doi: 10.1507/endocrj.42.413.

16. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724−763. doi: 10.1210/edrv.22.6.0451.

17. Radl DB, Zárate S, Jaita G, et al. Apoptosis of lactotrophs induced by D2 receptor activation is estrogen dependent. Neuroendocrinology. 2008;88(1):43−52. doi: 10.1159/000116117.

18. Colao A, Lombardi G, Annunziato L. Cabergoline. Expert OpinPharmacother. 2000;1(3):555–574. doi: 10.1517/14656566.1.3.555.

19. Stefaneanu L, Kovacs K, Scheithauer BW, et al. Effect of dopamine agonists on lactotroph adenomas of the human pituitary. Endocr Pathol. 2000;11(4):341−352. doi: 10.1385/ep:11:4:341.

20. Aoki MP, Aoki A, Maldonado CA. Sexual dimorphism of apoptosis in lactotrophs induced by bromocryptine. Histochem Cell Biol. 2001;116(3):215−222. doi: 10.1007/s004180100307.

21. Zornitzki T, Knobler H, Nass D, et al. Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma. Horm Res. 2004;61(3):111−116. doi: 10.1159/000075375.

22. Matsuyama J. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo). 2012;52(8):563−569. doi: 10.2176/nmc.52.563.

23. Ekramullah SM, Saitoh Y, Ohnishi T, et al. Effects of bromocriptine on staining indices of Ki-67 and proliferating cell nuclear antigen, and nucleolar organizer region number in pituitary adenomas. Neurol Med Chir (Tokyo). 1995;35(4):221−226. doi: 10.2176/nmc.35.221.

24. Lu C, Ren Z, Huan C, et al. The role of Ki-67 in women with a resistant prolactinoma: a retrospective analysis in 199 hospitalized patients over a period of 5 years. Pak J Pharm Sci. 2014;27(4 Suppl):1075−1081.

25. Delgrange E, Sassolas G, Perrin G, et al. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien). 2005;147(7):751−757. doi: 10.1007/s00701-005-0498-2.

26. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273−288. doi: 10.1210/jc.2010-1692.

27. Астафьева Л.И., Кадашев Б.А., Кутин М.А., Калинин П.Л. Осложнения лечения макропролактином агонистами дофамина // Вопросы нейрохирургии им. Н.Н. Бурденко. — 2011. — Т.75. — №2. — С. 41−50. [Astafeva LI, Kadashev BA, Kutin MA, Kalinin PL. Complications of treatment of prolactinoma by dopamine agonists. Burdenko’s journal of neurosurgery. 2011;75(2):41−50. (In Russ).]

28. Prevedello DM, Jagannathan J, Jane JA, et al. Relevance of high Ki-67 in pituitary adenomas. Case report and review of the literature. Neurosurg Focus. 2005;19(5):E11. doi: 10.3171/foc.2005.19.5.12.

29. Salehi F, Agur A, Scheithauer BW, et al. Ki-67 in pituitary neoplasms: a review. Part I. Neurosurgery. 2009;65(3):429−437. doi: 10.1227/01.NEU.0000349930.66434.82.

30. Landolt AM, Keller PJ, Froesch ER, et al. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet. 1982;2(8299):657−658. doi: 10.1016/s0140- 6736(82)92756-8.

31. Faglia G, Moriondo P, Travaglini P, et al. Influence of previous bromocriptine therapy on surgery for microprolactinoma. Lancet. 1983;1(8316):133−134. doi: 10.1016/s0140-6736(83)91782-8.

32. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. 3rd ed. World Health Organization classification of tumours. Lyon: IARC Press; 2004.

33. Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg. 2011;114(2):336–344. doi: 10.3171/2010.8.JNS10290.

34. Chiloiro S, Doglietto F, Trapasso B, et al. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 2015;101(2):143–150. doi: 10.1159/000375448.

35. Mete O, Lopes MB. Overview of the 2017 WHO Classification of Pituitary Tumors. Endocr Pathol. 2017;28(3):228−243. doi: 10.1007/s12022-017-9498-z.

36. Lopes MB. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017;134(4):521−535. doi: 10.1007/s00401-017-1769-8.